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A B S T R A C T
HMGB1 and HMGB2 are DNA-interacting proteins but can also have extracellular actions during inﬂammation.
Despite their relatively high homology, they may have distinct roles, making it essential to be able to diﬀer-
entiate between the two. Here we examine the speciﬁcity of ﬁve commercially-available anti-HMGB1 antibodies.
By Western blotting of recombinant proteins and HMGB1−/− mouse embryonic ﬁbroblasts, we identiﬁed only
one HMGB1 antibody that, under our experimental conditions, did not also detect HMGB2. Selecting speciﬁc
antibodies for HMGB1 and HMGB2 allowed identiﬁcation of distinct HMGB1 and HMGB2 subcellular pools in
primary neutrophils.
1. Introduction
HMGB1 and HMGB2 are members of the high mobility group box
(HMGB) protein family. Typically, these proteins aid DNA replication,
repair and transcription. However, HMGB1 shuttles between the nu-
cleus and cytoplasm. Cytosolic HMGB1 can be released from the cell
through active secretion, or passively released when membrane in-
tegrity is compromised (Scaﬃdi et al., 2002). Extracellular HMGB1 has
been extensively documented to act as an inﬂammatory cytokine
(Yamada and Maruyama, 2006). Although extracellular HMGB2 is re-
latively understudied, it may also have extracellular actions (Pusterla
et al., 2009).
Despite the high degree of sequence homology, and their structural
and biochemical similarities, HMGB1 and HMGB2 functions are not
identical. In knock-out studies, for example, HMGB1−/− but not
HMGB2−/− mice die shortly after birth due to hypoglycaemia
(Calogero et al., 1999), while HMGB2−/−males have reduced fertility
(Ronfani et al., 2001). In humans, an increased serum level of HMGB1
has been implicated in several inﬂammatory and autoimmune diseases
(Dupire et al., 2012), whereas overexpression of HMGB2 is associated
with tumour aggression in certain kidney and breast carcinomas (Kwon
et al., 2010). In summary, there are now many recent studies identi-
fying novel, non-redundant roles for HMGB1 and HMGB2.
A range of monoclonal and polyclonal antibodies have been gen-
erated for HMGB1 and HMGB2 and are commercially available. These
antibodies are often marketed as speciﬁc for HMGB1 or 2. In this study,
we screened ﬁve commercially-available HMGB1 antibodies for speci-
ﬁcity, evaluated through recombinant proteins and knock-out mouse
embryonic ﬁbroblasts. We found that most HMGB1 antibodies also
readily detected recombinant HMGB2 to some extent under our ex-
perimental conditions. Having identiﬁed speciﬁc antibodies for HMGB1
and−2, we found that these proteins have unique cellular locations in
primary human neutrophils but not in human endothelial cells, high-
lighting the need to be able to distinguish between these isoforms.
2. Materials and methods
2.1. Tissue culture
Human umbilical cord vein endothelial cells (HUVEC; PromoCell; c-
12203) were cultured in endothelial cell growth medium (PromoCell, c-
22010), containing 35 μg/ml gentamycin, 2% v/v fetal calf serum (FCS)
and endothelial cell growth supplements (Promocell, c-39215). WT and
HMGB1−/−mouse embryonic ﬁbroblasts (MEF) were kindly provided
by Professor S. Lippard (Massachusetts Institute of Technology,
Cambridge, MA). HMGB2−/− MEFs were purchased from
HMGBiotech (HM-251). MEFs were cultured in DMEM high glucose
(Sigma) with 1% v/v penicillin/streptomycin (Sigma) and 5% v/v FCS.
2.2. Western blotting
Lysates were made in RIPA lysis buﬀer and a protein inhibitor
cocktail (Sigma) was added to prevent protein degradation. Prior to gel
loading, lysate concentrations were established via Bradford assay. MEF
lysates, HUVEC, neutrophil lysates (10 μg) or 1 μg recombinant proteins
(ProSpec-PRO-581 & HMGBiotech-HM-153) were separated by SDS-
PAGE on 12% acrylamide gels under reducing or non-reducing condi-
tions, as indicated in the ﬁgure legend. Proteins were transferred to a
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PVDF membrane (MerckMillipore). Membranes were blocked for 1 h at
room temperature with 5% w/v BSA (Fraction V; Sigma) in TBST (Tris-
buﬀered saline containing 0.1% Tween-20), after which membranes
were incubated with a range of HMGB1 antibodies (see Fig. 1 and S.1)
or anti-HMGB2 antibodies (Rabbit monoclonal EPR6301; Abcam Cat#
ab124670; RRID: AB_10975355) at 4 °C for overnight incubation. After
washing with TBST and a 1 h 5% w/v milk block, membranes were
incubated for 2 h at room temperature with anti-rabbit HRP (Cell Sig-
naling Technology Cat# 7074) 1:5000, or anti-mouse HRP (Cell Sig-
naling Technology Cat# 7076) 1: 10,000, as appropriate. When ap-
propriate, anti-beta actin (Clone 8H10D10; Cell Signaling Technology
Cat# 3700, RRID:AB_2242334) or Anti-GAPDH (Clone 14C10; Cell
Signaling Technology Cat# 5014, RRID:AB_10693448) were used as
loading controls. Images were collected through chemiluminescent
substrate chemistry (Thermoﬁsher Cat# 34577) and documented on X-
ray ﬁlm (Amersham Hyperﬁlm ECL, VWR, Cat# 28–9068-35) and
developed using an OptiMax X-ray ﬁlm processor (Protec Medi-
zintechnik).
2.3. Primary cell isolation
Neutrophils were obtained from healthy volunteers who provided
their informed, written consent (local ethics committee approved).
Blood was collected in 4% sodium citrate. To isolate neutrophils, 25ml
of blood was layered on 15ml Histopaque-1077. Following cen-
trifugation (400×g, 30min, no break), the buﬀy coat layer was re-
moved to leave the erythrocyte/neutrophil pellet. The pellet was re-
suspended 1:1 v/v in Hanks buﬀered saline solution (HBSS, without
Ca2+ and Mg2+; Sigma), then diluted 1:1 in 2% Dextran-500 (made up
in HBSS). Erythrocytes were then left to settle for 20min at room
temperate before the upper (neutrophil layer) was collected, diluted
and pelleted in HBSS. The cell pellet was resuspended in ddH2O for 30 s
Fig. 1. Antibody epitope identiﬁcation. A) Schematic highlighting HMGB protein domains and conserved cysteine residues. B) Schematic demonstrating the three redox states of HMGB
proteins. C) Human and murine HMGB1 and HMGB2 amino acid alignments, shading is co-ordinated to represent degree of similarity, while unshaded regions indicate a residue
diﬀerence. Asterisk (*) deﬁnes conserved cysteine residues. Underlined residues locate the reported epitope regions (or central amino acid) for antibodies used within the screen. Note:
catalogue number not clone number used as the antibody reference.
Table 1
Antibody characteristics. CST, Cell Signaling Technology.
Catalogue number Clone Company RRID Species Monoclonal/Polyclonal Epitope reported by vendor
Ab92310 EPR3506 Abcam AB_10975355 Rabbit Monoclonal IPPKGETKKKFKDP
6893 D3E5 CST AB_10827882 Rabbit Monoclonal Alanine 137
3935 N/A CST AB_2295241 Rabbit Polyclonal Glycine 174
ADI-CSA-614-E KS1 Enzo Life Sciences AB_10631414 Mouse Monoclonal Arginine 70-Glutamine 72
MAB1690 115603 R&D Systems AB_2117897 Mouse Monoclonal Not available
Ab124670 EPR6301 Abcam AB_10975355 Rabbit Monoclonal Asparagine 7
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to lyse residual erythrocytes, after which the solution was diluted in
50ml HBSS and pelleted for immediate resuspension. Neutrophils were
used within 4 h of isolation.
2.4. Immunoﬂuorescence
HUVEC and MEF were grown to conﬂuence on glass coverslips prior
to 4% paraformaldehyde (PFA) ﬁxation for 20min at room tempera-
ture. After washing with PBS, cells were permeabilised with 0.1%
Triton-X100 for 10min. Neutrophils were ﬁxed (1% PFA) in suspension
to avoid activation with the glass coverslip, and permeabilised as
above. Neutrophils were then left to adhere for a minimum of 2 h at 4 °C
to poly-L-lysine-treated glass coverslips. After PBS washing, all samples
were incubated with anti-HMGB1 (CST 3935, 1:100) or anti-HMGB2
(Ab124670, 1:100) primary antibodies and left overnight in 33% v/v
FCS and 0.1% v/v sodium azide. Primary antibodies were removed, and
ﬂuorophore-conjugated anti-rabbit antibodies (Invitrogen Cat# 11-
4839-81) 1:200 were applied for 1 h at room temperature. Fluorescent
images were acquired by confocal scanning laser microscopy (Leica).
Microscope settings were optimised and kept constant for each cell
type.
3. Results
3.1. Epitope identiﬁcation of HMGB1 antibodies
Human amino acid sequences of HMGB1 and HMGB2 were sourced
from the National Centre for Biotechnology Information (NCBI). Amino
acid sequences were aligned using the free software, Jalview (Clamp
et al., 2004) to identify regions of homology (Fig. 1C). Using Jalview, it
was calculated that there is 79% sequence similarity between human
HMGB1 and human HMGB2. Both proteins contain two homologous
lysine-rich DNA-binding domains, A-Box and B-Box, and a highly ne-
gatively-charged C-terminal tail (Fig. 1A). Within the HMGB protein
there are three conserved cysteine residues (Fig. 1A). These play a key
role in producing unique redox forms, (Fig.1B), which regulate the
biological eﬀects of release HMGB proteins (Erlandsson Harris et al.,
2012).
There were three criteria for choosing antibodies for the screen: 1)
the antibody should be commercially and readily available from a
mainstream scientiﬁc retailer; 2) the antibody should be classiﬁed as
speciﬁc (in particular, there should be no apparent cross-reactivity with
HMGB2); 3) there should be minimal overlap wherever possible with
epitopes between antibodies used in the screen. Epitope regions for
HMGB1 were identiﬁed for each HMGB1 antibody within the screen by
contacting the manufacturers (Table 1). Unfortunately, due to protec-
tion of intellectual property many of the immunogen sequences were
Fig. 2. HMGB1 and HMGB2-speciﬁc antibody selection. A+B) Western blot of human recombinant (r)HMGB1 and rHMGB2. rHMGB1 was probed under reducing (+) and non-reducing
(−) conditions. All membranes were exposed for the same time to ensure comparability. Asterisks (*) on the left-hand side indicate the expected weight of his-tagged rHMGB1 and non-
tagged rHMGB2. C) Western blot of wildtype (WT), HMGB1−/− (MEF 1−/−) and HMGB2−/− (MEF2−/−) MEF lysates, under reducing conditions. Images are representative of 3
independent repeats.
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not divulged from the manufacturers. In these cases, centralised amino
acids of the epitopes were given. In the case of the antibody MAB1690,
R&D Systems stated that they do not conduct epitope mapping so were
unable to locate the exact address of their antibody.
3.2. HMGB1-speciﬁc antibody selection
His-tagged, recombinant human HMGB1 (~28 kDa) and (untagged)
recombinant human HMGB2 (~25 kDa) were subjected to SDS-PAGE
and Western blotting with each antibody. All antibodies were used at
their recommended concentration (Fig. S.1). Under our experimental
conditions, MAB1690 and 6893 readily detected HMGB2 in addition to
HMGB1 (Fig. 2A). Ab92310 weakly detected HMGB2. More intense
bands were observed under reducing conditions against the re-
combinant HMGB1, suggesting that all antibodies in this screen dis-
played higher aﬃnity for the reduced redox form of HMGB1. The non-
reduced protein ran slightly faster, suggesting that the single disulphide
bond inﬂuences the globular structure of the protein. Notably, Ab92310
could readily detect reduced HMGB1 but was particularly poor at de-
tecting non-reduced HMGB1. This means that Ab92310 might not de-
tect native HMGB1 if present in its non-reduced form. Some HMGB1
antibodies (MAB1690 and 6893) detected prominent bands at around
55 kDa and 50 kDa. This may represent dimers or aggregates forming at
high concentrations of recombinant HMGB1 protein. These bands were
also weakly detected by ADI-CSA-614-E, which also detected similar
bands with recombinant HMGB2 (despite not detecting monomer
HMGB2). Low molecular weight fragments were observed with all
HMGB1 antibodies except for 3935. This may represent recombinant
protein degradation products. In most cases these were only observed in
reduced samples. Based on these observations, we decided to use 3935
as our HMGB1-speciﬁc antibody.
Additionally, one HMGB2 antibody was trialled (Ab124670).This
antibody did not detect HMGB1 under our experimental conditions,
either in reduced or non-reduced forms, but readily detected HMGB2,
suggesting that it does speciﬁcally detect HMGB2. Interestingly,
Ab124670 is reported to bind to an epitope that varies by only one
amino acid between HMGB1 and HMGB2 in both mice and humans
(Fig. 1).
To test whether these antibodies retained speciﬁcity when used on
cell lysates, we took advantage of previously generated knock out MEF
HMGB1−/− and HMGB2−/− cell lines (Fig. 2B). Given the high
degree of sequence likeness for human and murine HMGB1 and
HMGB2, 99% and 97% respectively (Fig. S.2), it was assumed that MEF
cells would be a reliable cell line to work with. Anti-HMGB1 3935
readily detected HMGB1 in wild-type (WT) MEFs. This band was absent
in HMGB1−/− MEFs, and no other bands were observed. Conversely,
anti-HMGB2 Ab124670 readily detected a ~25 kDa protein in WT MEFs
that was absent in HMGB2−/− MEFs. In addition, there was a non-
speciﬁc band at ~36 kDa when MEFs were probed with Ab124670.
3.3. HMGB1 is diﬀerentially located in neutrophils compared to HMGB2
To demonstrate the importance of speciﬁc antibodies for HMGB1
and HMGB2, endothelial cells (HUVEC) and primary human neu-
trophils were stained to identify HMGB1 and HMGB2 cellular locations
by confocal microscopy. HMGB1 and HMGB2 were both nuclear in
HUVEC (Fig. 3A). In contrast, HMGB1 and HMGB2 had distinct loca-
tions in neutrophils. HMGB1 in resting neutrophils was predominantly
cytosolic and distributed in puncta, whereas HMGB2 was retained in
the nucleus (Fig. 3B). Appropriate IgG controls were carried out (Fig.
Fig. 3. Subcellular locations of HMGB1 and HMGB2 are cell type speciﬁc. Confocal microscopy images of HUVEC (A) and neutrophils (B) using a 63× oil immersion lens. HMGB1 (3935)
and HMGB2 (EPR6301) proteins are shown in red, and blue is the nuclear stain (DAPI). Scale bar is 50 μm in both. The cell marked with the white arrow in the merge is shown in higher
magniﬁcation in the ﬁnal panel. Images are representative of 3 independent repeats. Western blot of HUVEC (C) and neutrophil (D) reduced lysates. 1–3 indicate three diﬀerent lysates
prepared independently. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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S.3). Finally, we tested whether the two antibodies used could speciﬁ-
cally detected HMGB1 and HMGB2 in HUVEC and neutrophils by
Western blot (Fig. 3C–D). A single band (~25 kDa) was observed for
each protein in each cell type. Notably, the non-speciﬁc band
(~36 kDa) found when MEF lysates were probed with anti-HMGB2
(Ab124670) was not seen in either HUVEC or neutrophil lysates. Cy-
toplasmic HMGB1 in neutrophils has been previously shown to be due
to mono-methylation of Lys42 (Ito et al., 2007). However, to the best of
our knowledge this is the ﬁrst example of HMGB1 and HMGB2 being
diﬀerentially localised within the same cell, which leads to speculation
that these 79% homologous proteins may have diﬀerent biological
functions in neutrophils.
In conclusion, some commercially-available HMGB1 antibodies
cross-reacted with the highly homologous recombinant protein,
HMGB2, under our experimental conditions. We selected two speciﬁc
HMGB1 and HMGB2 antibodies based on Western blot analysis from
recombinant proteins and MEF lysates deﬁcient in HMGB1 or HMGB2.
By using these speciﬁc antibodies, we demonstrated that although
HMGB1 and HMGB2 are identically localised to the nucleus in en-
dothelial cells, in neutrophils HMGB2 remained nuclear and HMGB1
cytoplasmic. This suggests that HMGB1 and 2 may have distinct roles in
neutrophils, and highlights the importance of antibody speciﬁcity,
especially when working with primary cells which are not genetically
tractable.
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